[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612487":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":31,"responsibleParty":118,"collaborators":26,"id":122,"slug":26,"hasResults":123,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":123,"sex":129,"minAge":130,"maxAge":26,"enrollmentInfo":131,"targetDuration":26,"studyType":134,"phases":135,"briefSummary":137,"conditions":138,"keywords":143,"overallStatus":153,"whyStopped":26,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":163},{"fullName":5,"class":6},"Shiraz University of Medical Sciences","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention","ACTIVE_COMPARATOR","Consumption of 20 milligrams rosuvastatin daily",[13],"Drug: Rosuvastatin 20 mg\u002Fday",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo (placebo tablets similar to rosuvastatin)",[19],"Drug: Placebo tablets similar to rosuvastatin 20mg tablets",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Rosuvastatin 20 mg\u002Fday","Consumption of rosuvastatin 20mg tablets every day",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo tablets similar to rosuvastatin 20mg tablets","consumption of placebo tablets similar to rosuvastatin 20mg",[15],[32,50,60,74,88,98,108],{"facility":33,"status":26,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Motahari Breast Cancer Clinic","Shiraz","Fars","71344-1864","Iran",{"type":39,"coordinates":40},"Point",[41,42],52.53113,29.61031,{"lat":42,"lon":41},[45],{"name":46,"role":47,"phone":26,"phoneExt":48,"email":49},"Armin Attar, Associate Professor","CONTACT","+98 71 3612 10","attar_armin@yahoo.com",{"facility":51,"status":26,"city":34,"state":35,"zip":26,"country":37,"cosmosGeoPoint":52,"geoPoint":54,"contacts":55},"Kowsar Hospital, Fars Heart Foundation",{"type":39,"coordinates":53},[41,42],{"lat":42,"lon":41},[56],{"name":57,"role":47,"phone":58,"phoneExt":26,"email":59},"Masoud Sayad","+98 71 3614 1000","masoud.sayad@yahoo.com",{"facility":61,"status":26,"city":62,"state":63,"zip":26,"country":37,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Toba Oncology Department, Mazandaran University of Medical Sciences","Sari","Mazandaran",{"type":39,"coordinates":65},[66,67],53.06009,36.56332,{"lat":67,"lon":66},[70],{"name":71,"role":47,"phone":72,"phoneExt":26,"email":73},"Maryam Nabati","+98 11 3304 4000","dr.mr.nabati@gmail.com",{"facility":75,"status":26,"city":76,"state":77,"zip":26,"country":37,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Modarres Hospital, Shahid Beheshti University of Medical Sciences","Tehran","Tehran Province",{"type":39,"coordinates":79},[80,81],51.42151,35.69439,{"lat":81,"lon":80},[84],{"name":85,"role":47,"phone":86,"phoneExt":26,"email":87},"Shabnam Kazemloo","+98 21 23515","kazemloo.shabnam@sbmu.ac.ir",{"facility":89,"status":26,"city":76,"state":77,"zip":26,"country":37,"cosmosGeoPoint":90,"geoPoint":92,"contacts":93},"Rajaee Hospital, Iran University of Medical Sciences",{"type":39,"coordinates":91},[80,81],{"lat":81,"lon":80},[94],{"name":95,"role":47,"phone":96,"phoneExt":26,"email":97},"Azin Alizadehasl","+98 21 3455 2001","alizadeasl@gmail.com",{"facility":99,"status":26,"city":76,"state":77,"zip":26,"country":37,"cosmosGeoPoint":100,"geoPoint":102,"contacts":103},"Sina Hospital, Tehran University of Medical Sciences",{"type":39,"coordinates":101},[80,81],{"lat":81,"lon":80},[104],{"name":105,"role":47,"phone":106,"phoneExt":26,"email":107},"Zahra Shajari","+98 21 6634 8587","adz.shajari@gmail.com",{"facility":109,"status":26,"city":76,"state":77,"zip":26,"country":37,"cosmosGeoPoint":110,"geoPoint":112,"contacts":113},"Taleghani Hospital, Shahid Beheshti University of Medical Sciences",{"type":39,"coordinates":111},[80,81],{"lat":81,"lon":80},[114],{"name":115,"role":47,"phone":116,"phoneExt":26,"email":117},"Alireza Farzaei","+98 21 2243 2566","alirezafarzaei@gmail.com",{"type":119,"investigatorFullName":120,"investigatorTitle":121,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Armin Attar","Prof. Armin Attar","100612487",false,"NCT07254221","Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients","Evaluation of Rosuvastatin Efficacy in Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients After Chemotherapy","ROSUBREAST","Inclusion Criteria:\n\n* Female individuals with ≥18 years of age\n* Documented breast cancer diagnosis based on imaging and pathology findings\n* Scheduled to receive the first time anthracycline-based chemotherapy\n\nExclusion Criteria:\n\n* Baseline LVEF \\\u003C 50%\n* Prior Statin use or Statin use is indicated based on guidelines\n* history of congestive heart failure (CHF) or cardiomyopathy\n* Pregnancy or breastfeeding\n* Unable to provide informed consent\n* Unexplained persistent elevation of transaminases (\\>3 times upper limits of normal)\n* Concomitant use of oral cyclosporine\n* Metastatic invasion of cancer to other organs\n* Previous cycles of chemotherapy\n* Any contraindication for statin use","FEMALE","18 Years",{"count":132,"type":133},400,"ESTIMATED","INTERVENTIONAL",[136],"PHASE4","This study, called \"ROSUBREAST\", is a multicenter, double-blind, randomized clinical trial evaluating whether rosuvastatin (20 mg daily) can protect the heart in women with breast cancer receiving anthracycline-based chemotherapy. A total of 400 participants will be randomly assigned to receive either rosuvastatin or placebo for 12 months. The main goal is to determine whether rosuvastatin can prevent cancer treatment-related cardiac dysfunction (CTRCD), defined as a significant drop in heart pumping function. The study will also assess changes in cardiac strain, blood biomarkers, symptoms of heart failure, quality of life, and possible side effects.",[139,140,141,142],"Anthracycline-induced Cardiac Toxicity","Breast Cancer","Anthracycline Related Cardiotoxicity in Breast Cancer","Anthracycline-induced Cardiotoxicity",[144,145,146,147,148,149,150,151,152],"Breast cancer","rosuvastatin","statin therapy,","cancer-related treatment cardiac dysfunction","anthracycline induced cardiomyopathy","cardiac dysfunction","cardiotoxicity","chemotherapy","anthracycline","NOT_YET_RECRUITING","2025-12-03",{"date":156,"type":157},"2025-12-10","ACTUAL",{"date":159,"type":133},"2026-02-01",{"date":161,"type":133},"2028-04-21",{"name":5,"class":6},7]